Pneumococcal disease threat in Africa

23 March 2009

Two new studies from the Pneumococcal Awareness Council of Experts highlight the increased risk for children in Africa of contracting  pneumococcal disease and suffering its devastating consequences. The  studies were presented at the USA-based Sabin Vaccine Institute's Fourth  Regional Pneumococcal Symposium in Johannesburg, South Africa. According  to the PACE, the findings reinforce the urgent need for improving access  to life-saving vaccines and treatments throughout the continent. The  South African Ministry of Health was congratulated for its leadership in  making South Africa the first country in Africa to introduce  pneumococcal vaccine (Marketletter September 21, 2008)

Cirode Quadros, executive vice president of the Sabin Vaccine Institute  and co-chairman of the PACE, said: "in light of the risks and  devastating consequences of pneumococcal disease, particularly in  Africa, protecting African children from this disease is an urgent  priority. We urge countries in Africa and throughout the developing  world to follow South Africa's example and ensure vaccines are available  to those that need them most."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight